Department of Medicine, University of Pennsylvania, Philadelphia, PA 15213, USA.
Pancreatology. 2013 Jul-Aug;13(4):336-42. doi: 10.1016/j.pan.2013.05.002. Epub 2013 May 17.
Diabetes and glucose intolerance are common complications of chronic pancreatitis, yet clinical guidance on their detection, classification, and management is lacking.
A working group reviewed the medical problems, diagnostic methods, and treatment options for chronic pancreatitis-associated diabetes for a consensus meeting at PancreasFest 2012.
Guidance Statement 1.1: Diabetes mellitus is common in chronic pancreatitis. While any patient with chronic pancreatitis should be monitored for development of diabetes, those with long-standing duration of disease, prior partial pancreatectomy, and early onset of calcific disease may be at higher risk. Those patients developing diabetes mellitus are likely to have co-existing pancreatic exocrine insufficiency. Guidance Statement 1.2: Diabetes occurring secondary to chronic pancreatitis should be recognized as pancreatogenic diabetes (type 3c diabetes). Guidance Statement 2.1: The initial evaluation should include fasting glucose and HbA1c. These tests should be repeated annually. Impairment in either fasting glucose or HbA1c requires further evaluation. Guidance Statement 2.2: Impairment in either fasting glucose or HbA1c should be further evaluated by a standard 75 g oral glucose tolerance test. Guidance Statement 2.3: An absent pancreatic polypeptide response to mixed-nutrient ingestion is a specific indicator of type 3c diabetes. Guidance Statement 2.4: Assessment of pancreatic endocrine reserve, and importantly that of functional beta-cell mass, should be performed as part of the evaluation and follow-up for total pancreatectomy with islet autotransplantation (TPIAT). Guidance Statement 3: Patients with pancreatic diabetes shall be treated with specifically tailored medical nutrition and pharmacologic therapies.
Physicians should evaluate and treat glucose intolerance in patients with pancreatitis.
糖尿病和葡萄糖耐量异常是慢性胰腺炎的常见并发症,但目前缺乏关于其检测、分类和管理的临床指南。
一个工作组在 2012 年 PancreasFest 上对慢性胰腺炎相关糖尿病的医学问题、诊断方法和治疗选择进行了审查,为共识会议提供了参考。
指南声明 1.1:糖尿病在慢性胰腺炎中很常见。虽然任何慢性胰腺炎患者都应监测是否发生糖尿病,但那些疾病持续时间长、曾行部分胰腺切除术和早期发生钙化性疾病的患者可能风险更高。那些发生糖尿病的患者可能同时存在胰腺外分泌功能不全。指南声明 1.2:继发于慢性胰腺炎的糖尿病应被视为胰源性糖尿病(3c 型糖尿病)。指南声明 2.1:初始评估应包括空腹血糖和 HbA1c。这些检查应每年重复。空腹血糖或 HbA1c 任何一项受损都需要进一步评估。指南声明 2.2:空腹血糖或 HbA1c 任何一项受损都需要进一步通过标准的 75 g 口服葡萄糖耐量试验进行评估。指南声明 2.3:混合营养摄入后胰多肽反应缺失是 3c 型糖尿病的特异性指标。指南声明 2.4:评估胰腺内分泌储备,特别是功能性β细胞量,应作为胰岛自体移植(TPIAT)全胰切除术评估和随访的一部分。指南声明 3:胰腺糖尿病患者应采用专门定制的医学营养和药物治疗。
医生应评估和治疗胰腺炎患者的葡萄糖耐量异常。